|
Guilford Announces Private Placement of $59 Million of Common Stock BALTIMORE, June 11 /PRNewswire/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) today announced that it has entered into definitive agreements for the private placement of an aggregate of 3,000,000 newly issued shares of Guilford Common Stock to selected institutional investors. The aggregate proceeds from the private placement will be $59,100,000 before the deduction of expenses and placement agent commissions. The purchase price per share is $19.70. CIBC World Markets Corp. served as placement agent for the private financing. The equity capital raised from the sale of the Common Stock will provide Guilford with additional resources to expand its commercial operations, including increasing its activities related to the commercialization of GLIADEL(R) Wafer internationally, and to expand its internal resources to support its increased clinical development activities. Guilford Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development of biopolymer-based therapeutics for cancer and other diseases, and novel products for the diagnosis and treatment of neurological disorders. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison - 410.631.5022 or (cell) 410.274.5266 Angela Rubin - 410.631.6449 Internet: http://www.guilfordpharm.com This press release contains forward-looking statements that involve risks and uncertainties, including those described in the section entitled "Risk Factors" contained in the Company`s Annual Report on Form 10-K for the year ended December 31, 2000, that could cause the Company`s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Among other things, there can be no assurance that the results of the third multi-center Phase III clinical trial will support approval of GLIADEL(R) Wafer in the U.S., Europe and elsewhere for treatment of patients with malignant glioma at the time of first surgery. |
|
| aus der Diskussion: | GUILFORD PHARMACEUTICALS - PART III |
| Autor (Datum des Eintrages): | Maiestro (13.06.01 18:27:25) |
| Beitrag: | 20 von 66 (ID:3731716) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |